- Home
- NFE vs EBS Comparison
NFE vs EBS Comparison
Compare NFE & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NFE | EBS |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.4M | 312.8M |
| IPO Year | 2018 | 2006 |
Fundamental Metrics
Financial Performance| Metric | NFE | EBS |
|---|---|---|
| Price | $0.28 | $6.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $5.50 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 1.8M | 1.6M |
| Earning Date | 04-13-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 125.83 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,504,037,000.00 | $742,900,000.00 |
| Revenue This Year | $110.34 | $1.29 |
| Revenue Next Year | $3.54 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.25 | $4.36 |
| 52 Week High | $3.08 | $14.06 |
Technical Indicators
Market Signals| Indicator | NFE | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 36.99 | 51.64 |
| Support Level | $0.25 | $4.36 |
| Resistance Level | $0.37 | $8.59 |
| Average True Range (ATR) | 0.02 | 0.31 |
| MACD | 0.00 | 0.23 |
| Stochastic Oscillator | 34.16 | 75.12 |
Price Performance
Historical ComparisonAbout NFE New Fortress Energy Inc.
New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.